In a deal described by the two companies as a “strategic alliance,” AbbVie has paid iStar Medical SA $60m to continue the development and commercialization of iSTAR’s MINIject glaucoma device.
The upfront payment will “go straight to supporting us advance the further clinical and commercial development of MINIject,” iSTAR Medical CEO Michel Vanbrabant told Medtech Insight.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?